DETECTION OF BCL-2 GENE MAJOR BREAKPOINT REGION REARRANGEMENT IN HUMAN B-CELL LYMPHOMAS

Objective To investigate the frequency of t(14; 18) in different subtypes of B-cell lymphomas and the ability or the polymerase chain reaction(PCR) to detect this rearrangement in frozen samples. Methods 1o7 cases of B-cell lymphomas were studied uslng DNA extracted from rresh-frozen tissues. The DNA samples were amplified by PCR for bcl-2 MBR/JH. The products of bcl-2/JH rearrangement were hybridized with an internal olignucleotide probe or bcl-2 MBR. Results The rearranged bcl-2MBR/JH gene was detected in 13 of the 25(52. o% ) follicular center lymphomas, according to REAL classification: 8 of 11 (72. 7%) grade 1, 2 of 5(40. 0%) grade I, and 3 of 90 (33. 3%) grade, 17 of 82(2o. 8%) cases or difruse large B-cell lymphomas were found to have detectable bel-2 MBR/J. rearrangement- Conclusion The rrequency or bcl-2 MBR/JH rearrangement in diffuse large B-cell lymphomas is significantly lower than those in follicular center lympkomas(X2= 9. 28, P <o. oo5), suggesting that bcl2/JH rearrangements occur mainly in follicular center lymphomas. in addition, the result of reconstruction experiments suggest that amplification or bcl-2 MBR/JH rearrangements by PCR is both sensitive and specific for detection of t (14; 18 ) translocation.

The Expression and Significance of CyclinD2 and Bcl-2 in Diffuse Large B-cell Lymphoma

Objective:To study the expression and significance of cyclinD2 and Bcl-2 in diffuse large B-cell lymphoma.Methods:This project used immunohistochemical methods to detect the expression of cyclinD2 and Bcl-2 in 120 cases of diffuse large B-cell lymphoma and 80 cases of reactive hyperplasia of lymphoid tissue.The materials were collected from the hospital from January 2018 to 2020.In March 2015,120 patients had lymphoma tissue removed during the month of surgery.The postoperative pathological diagnosis was DLBCL.Another 80 cases of lymphoid hyperplasia(RLH)tissues were selected as controls.Results:CyclinD2 and BCL-2 expression were not statistically different in patients with diffuse large B-cell lymphoma in different ages,genders,locations,tissue types,and degree of differentiation;but statistically significant in different Ann Arbor stages,immunotypes,IPI index and first treatment efficacy.Conclusion:This research not only has important theoretical value,but also important economic value and social significance.

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP

Objective:Limited data about the prognostic significance of BCL2 mutations and BCL2 copy number variations in diffuse large B-cell lymphoma(DLBCL)are available.This study aimed to comprehensively describe BCL2 genetic alterations in DLBCL patients,and examine correlation of BCL2,TP53 and other genetic alterations with outcomes in patients treated with R-CHOP.Methods:Probe capture-based high-resolution sequencing was performed on 191 patients diagnosed with de novo DLBCL.MYC,BCL2,and BCL6 protein expressions were detected by immunohistochemistry.Results:The presence of BCL2 alterations significantly correlated with poor progression-free survival(PFS)(5-year PFS:13.7%vs.40.8%;P=0.003)and overall survival(OS)(5-year OS:34.0%vs.70.9%;P=0.036).Importantly,patients who harbored BCL2 gain/amplifications(BCL2GA/AMP)also had a remarkably inferior 5-year PFS(11.1%vs.38.3%;P<0.001)and OS(22.1%vs.69.6%;P=0.009).In contrast,neither BCL2 mutations nor BCL2 translocations were significantly prognostic for survival.Multivariable analyses showed that the presence of BCL2 alterations,especially BCL2GA/AMP,TP53 mutations,and International Prognostic Index(IPI)were significantly associated with inferior PFS and OS.Novel prognostic models for OS were constructed based on 3 risk factors,including BCL2 alterations(Model 1)or BCL2GA/AMP(Model 2),TP53 mutations,and IPI,to stratify patients into 4 risk groups with different survival outcomes.Conclusions:This study showed that DLBCL patients treated with R-CHOP,BCL2 alterations,especially BCL2GA/AMP and TP53 mutations were significantly associated with inferior outcomes,which were independent of the IPI.The novel prognostic models we proposed predicted outcomes for DLBCL patients treated with R-CHOP,but further validation of the prognostic models is still warranted.

Bcl-2 GENE REARRANGEMENT DETERMINED BY PCR AS AMEAN TO DETECT MINIMAL RESIDUAL DISEASE INMALIGNANT LYMPHOMAS

Objective: To develop a sensitive method to detect minimal residual disease and to elucidate the significance of bcl-2 gene rearrangement in diagnosis and treatment of malignant lymphoma. Methods: Using polymerase chain reaction (PCR) to detect bcl-2 gene rearrangement and using serial dilution method to define the sensitivity of PCR. Results: In 9 different malignant lymphoma cell lines, Su-DHL-4 and Su-DHL-6 were shown bcl-2(MBR)/JH rearrangement, the sensitivity of PCR was 1:105. In 16 patients with follicular lymphoma, the peripheral blood and bone marrow were PCR positive in 4 cases both at initial diagnosis and after complete remission. Conclusion: Detection of bcl-2 gene rearrangement by PCR provides a sensitive and specific assay of minimal residual disease. It is helpful to improve staging of disease, prognosis and evaluation of the treatment results.

Total saponins in Rubus parvifolius L.induce lymphoma cells apoptosis through upregulated Bax/Fas and downregulated Bcl-2 in vivo and in vitro

Purpose:To investigate the effect of total saponins of Rubus parvifolius L.(TSRP)on lymphoma Raji cells and further discuss its mechanism.Methods:The model of nude mice bearing Raji cells was established,the volume,weight and inhibition rate of the transplanted tumor were analyzed and compared after different concentrations of TSRP treatment.Cell apoptosis and expression of Bcl-2,Bax,Fas proteins were detected by TUNEL and immunohistochemiscal method respectively.Effects of TSRP on cell proliferation were tested with MTT assay in vitro.Cell apoptosis and expression of Caspase-9,Caspase-3,Bcl-2,Bax and Fas proteins were tested with DAPI staining and Western blot.Results:TSRP significantly reduced the volume and tumor weight of Raji subcutaneous transplanted tumor and induced the apoptosis of Raji cells in vivo.The tumor inhibition rate of high-dose(100 mg/kg)TSRP is 90.84%.The TUNEL test results show that the fluorescence intensity of the tumor issue treated with TSRP is significantly improved.Compared with the control group,the fluorescence intensity of high-concentration TSRP is 82.43 ± 7.81,which is significantly different(P<0.001).The results of immunohistochemistry test showed that the Bcl-2 expression of Raji cell treated with TSRP is obviously reduced,and Bax expression is obviously increased.Meanwhile,compared with that of control group,Fas expression is obviously reduced.MTT assay showed that TSRP can significantly inhibit proliferation of Raji cells with dose dependence.The inhibition rate of 400 μg/mL TSRP is 53.46 ± 4.90%(P<0.001).DAPI staining results showed that TSRP can significantly induce cell apoptosis.According to Western blot results,it is found that TSRP can significantly inhibit activity of Bcl-2 and increase Bax expression,and TSRP can also inhibit Fas expression.Meanwhile,expression of Caspase-9 and Caspase-3 is also increased.Conclusion:TSRP could inhibit the proliferation of lymphoma via induction of apoptosis in a time and dose-dependent manner.Apoptotic signaling induced by TSRP was characterized by up-regulating Bax,Fas and Caspase-8 protein expression,and down-regulating of Bcl-2 protein expression.

Detection of apoptotic cells and immunohistochemical study of bcl-2 and p53 gene protein in primary gastric mucosa-associated lymphoid tissue (MALT) lymphoma

To identify the apoptotic cells in gastric MALT lymphoma and its relationship between bcl-2 and p53 gene expression. Methods: TdT-mediated dUTP biotin Nick End labeling (TUNEL) and immuno-histochemistry ABC method were used to display apoptotic cells and the gene protein expression of bcl-2 and p53 independently. Results: Apoptotic indices (AI) in high-grade MALT lymphomas were significantly higher than in mixed-grade group and low-grade group (P<0.05). Bcl-2 was expressed in 83% of low-grade tumors, 61.6% of the median-grade tumors and 43.7% of high-grade tumors. An inverse correlation was observed between the expression of bcl-2 and apoptotic indices. Only 27 cases were p53 positive. The frequency of p53 positivity was significantly increased as the histologic grade advanced (P<0.05). There was also an inverse correlation between the expression of bcl-2 and p53. Conclusion: Apoptosis may be important in tumors development and transmission. p53 and bcl-2 were important regulatory genes of apoptosis and may be associated with transformation from low- grade to high-grade lymphomas.

CHOP-like Regimen in Combination with Rituximab and Peginterferon Alpha-2b in Newly-diagnosed Diffuse Large B-cell Non-Hodgkin＇s Lymphoma： Experience in a Chinese Center

OBJECTIVE To evaluate the efficacy of rituximab combined with CHOP-like regimen with or without IFN in patients newly diagnosed diffuse large B-cell Non-Hodgkin＇s lymphoma （DLBCL）.METHODS From January 2003 to July 2008, 51 patients received CHOP-like chemotherapy （cyclophosphamide 750 mg/m2, epirubicin 80 mg/m2, vindesine 2.8 mg/m2 on day 1, and prednisolone 100 mg/day on day 1 to day 5）. Thirty-one patients received CHOPR-like treatment （rituximab 375 mg/m2 1 day before CHOP-like chemotherapy）. Twenty patients received CHOP-like regimen in combination with peginterferon （pegIFN） （1μg/kg on day 5） and rituximab （on day 6）.RESULTS -The CR （complete remission） rate in the CHOPR-like （with or without pegIFN） group and in the CHOP-like group was 78.4% and 45.1% （P = 0.005）, respectively. The estimated mean time of overall survival （OS） in the CHOPR-like group and CHOP- like group was 58.7 ± 2.8 and 36.4 ±3.4 months, respectively （P = 0.002）. The rates of CR and OR （overall remission） in CHOPR- like with IFN arm were 85.0% and 95.0%, and the rates of those in CHOPR-like without IFN arm were 74.2% and 87.0% （P 〉 0.05）. The estimated mean time of 4-year-PFS （progression- free survival） in CHOPR-like with IFN arm and in CHOPR-like without IFN arm was 62.9 ±3.0 months and 51.0 ± 4.6 months （P = 0.092）, respectively. In the CHOPR-like with IFN arm, no patient relapsed after achieving CR, while the estimated rate of 4-year- DFS （disease-free survival） in the patients who reached CR in the CHOPR-like without IFN arm was （63.4 ± 19.3）% （P = 0.061）. CONCLUSION Rituximab combined with CHOP-like chemotherapy improved the prognosis of DLBCL patients. The IFN may help to improve the quality and duration of response of DLBCL patients treated with rituximab and CHOP-like regimen.

Bcl-2 Small Interfering RNA Inhibits the Growth of Human Lymphoma Transplanted Subcutaneously in Nude Mice

OBJECTIVE To investigate whether small hairpin RNA (shRNA)targeting Bcl-2 mRNA could inhibit the growth of lymphomatransplanted subcutaneously in nude mice.METHODS Recombinant Bcl-2 shRNA expression vector withgreen fluorescence protein (GFP) gene was constructed andpreserved in our lab. We evaluated the antitumor effect of the Bcl-2shRNA in vivo which was the model of nude mice bearing Rajicells xenografts. Human Raji cells were injected subcutaneouslyinto nude mice to establish lymphoma models. When thediameters of tumor were above 0.5 cm after Raji cells injection,the mice bearing tumor were randomly divided into four groups:saline control group, negative shRNA group, plasmid vectorgroup, Bcl-2 shRNA group. The polyethylenimine (PEI) was usedto transfect shRNA into tumor. The mixed PEI and shRNA wasinjected into tumors. The growth and size of tumor were observed.Tissue was stained by H&E for its pathological morphology. Theexpression of Bcl-2 mRNA in the tumor mass was detected byreverse transcription polymerase chain reaction (RT-PCR).RESULTS A significant difference in median tumor weightwas observed in mice treated with Bcl-2 shRNA, compared withthose in the groups of negative shRNA or plasmid vector or salinesolution (P< 0.05). Pathological evaluation was completed in allexcised tumors from nude mice bearing Raji cells xenografts.The tumor tissue of the mice treated with Bcl-2 shRNA showedapoptosis, serious necrosis of the cells and inflammatory cellsinfiltration. There was no change in the morphology of cellsamong negative shRNA, plasmid vector and saline solution group.In the group of the Bcl-2 shRNA, the expression levels of Bcl-2mRNA of the tumor tissue were effectively inhibited (P < 0.05).CONCLUSION The shRNA targeting at the Bcl-2 mRNAcould inhibit the growth of human lymphoma transplantedsubcutaneously in nude mice.

Effect of rituximab combined with CVAD regimen on serum VEGF and β2-MG levels in patients with primary gastrointestinal B-cell lymphoma

Objective:To investigate the clinical effect of rituximab combined with CVAD regimen in patients with primary gastrointestinal B-cell lymphoma and serum vascular endothelial growth factor (VEGF) andβ2 microglobulin (β2-MG) The impact of the level.Methods:Eighty-four patients with primary gastrointestinal B-cell lymphoma treated from May 2014 to December 2015 were enrolled. Based on the random number table, all the patients were divided into a control group (n=42) and an observation group (n=42). The control group was treated with CVAD. The observation group was treated with rituximab on the basis of the control group. The effect of the patients was evaluated after 3 courses of treatment. The patients were followed up for 3 years after treatment. US RECIST 1.1 was used to evaluate the short-term efficacy on the patients;VEGF, TNF receptor-associated factor 6 (TRAF6) and B-cell lymphoma factor-6 (Bcl-6) levels were measured by enzyme-linked immunosorbent assay;β2-MG level test was implemented to compare the short-term efficacy, biochemical indicators, incidence of toxic side effects and long-term survival rate of the two groups. Results: The short-term efficacy rate of the observation group was 76.19%, which was higher than that of the control group (50.00%) (P<0.05). The levels of VEGF, TRAF6, Bcl-6, andβ2-MG were lower in the observation group after 3 courses of treatment than that in the control group (P<0.05);there was no significant difference in the incidence of neutropenia, gastrointestinal reactions, sepsis, infection, infusion-related reactions and cardiovascular events between the observation group and the control group (P>0.05);The 1-year long-term survival rate after treatment was not statistically significant (P>0.05). The long-term survival rate of the observation group was higher than that of the control group at 2 and 3 years after treatment (P<0.05).Conclusion: The combination of rituximab and CVAD in patients with primary gastrointestinal B-cell lymphoma can improve short-term efficacy, lower VEGF andβ2-MG levels, and lower incidence of side effects. It can improve the long-term survival rate of patients and is worthy of promotion and application.

针刺介入时机对缺血性中风大鼠神经功能评分和Bcl-2、Bax表达的影响

目的研究不同时间点介入针刺治疗对缺血性中风大鼠神经功能评分和对缺血脑组织中B细胞淋巴瘤/白血病-2(B cell lymphoma/lewkmia-2,Bcl-2)、Bcl-2相关X蛋白(Bcl-2 associated X protein,Bax)阳性表达的细胞数量的影响,探讨针刺治疗机制及介入时机。方法将200只雄性SD大鼠随机分为假手术组、模型组、2小时针刺组、72小时针刺组和168小时针刺组5组,除假手术组外,均采用线栓法制备大鼠局灶性永久性脑缺血模型,在术后1、3、7、14天,4个时间点采用Garcia复合评分法评价大鼠神经功能,用酶联免疫分析法探查缺血脑组织中的Bcl-2、Bax蛋白表达情况,并在显微镜下记录阳性细胞数目进行比较。结果针刺各组缺血性中风大鼠神经功能评分得到明显改善,优于模型组(P<0.001);2小时针刺组分别优于72小时、168小时组(P<0.01),差异有统计学意义。缺血性中风大鼠术后不同时间点脑组织中的Bcl-2,Bax表达均增高,1天达到高峰,随后下降,与假手术组比较有统计学意义(P<0.001,P<0.01)。术后2小时与模型组、72小时、168小时针刺组比较,可明显提高Bcl-2蛋白的表达、抑制Bax蛋白的表达,差异有统计学意义(P<0.001);72小时与168小时针刺组比较可明显提高Bcl-2蛋白的表达、抑制Bax蛋白的表达,差异有统计学意义(P<0.01)。结论针刺可明显提高缺血性中风大鼠的Garcia评分,改善其运动、感觉和协调功能;针刺可通过调节Bcl-2、Bax蛋白表达来抑制神经细胞凋亡,挽救缺血半暗带神经细胞的功能,而且在缺血性中风后越早介入针刺治疗疗效越好,存在一个最佳治疗时间窗。

PTEN与Bcl-2在鼻咽癌中的表达及意义

目的观察PTEN与Bcl-2在鼻咽癌(NPC)中的表达情况,探讨两者的表达及其联合表达在NPC发生、发展、侵袭和转移过程中的可能作用。方法采用免疫组织化学染色法,观察50例NPC石蜡标本和15例正常鼻咽黏膜标本中PTEN与Bcl-2的蛋白表达情况。结果正常鼻咽组织中,PTEN呈强阳性表达,而Bcl-2的表达仅局限在上皮层的基底细胞层。NPC中,PTEN阳性表达率为22.0%(11/50),Bcl-2为82.0%(41/50),与正常组比较,差异均有统计学意义。两者在NPC的表达强度无明显相关(r=-0.109,P=0.453)。结论在NPC组织中,PTEN的低表达或表达缺失和Bcl-2强阳性表达可能协同参与了NPC的发生,而在NPC的发展、浸润和转移过程中,两者未能表现出明显的相关性。

胸腺瘤表皮生长因子受体、增殖细胞核抗原、Bcl-2和Bax表达及临床意义

目的 探讨胸腺瘤表皮生长因子受体 ( EGFR)、增殖细胞核抗原 ( PCNA)、Bcl- 2和 Bax的表达与胸腺瘤临床病理特征的关系及临床意义。 方法 应用免疫组织化学链霉素亲生物蛋白 -过氧化酶 ( S- P)法检测 4 6例胸腺瘤患者EGFR、PCNA、Bcl- 2和 Bax的表达。 结果 胸腺瘤 EGFR阳性表达率为 71.7% ,PCNA标记指数为 4 .0 0 %± 1.87% ,Bcl- 2、Bax阳性率分别为 4 1.3 %、15 .2 %。EGFR表达与胸腺瘤 Masaoka分期、肿瘤性质有明显关系 ,EGFR阴性者术后生存率显著高于阳性者 ( P=0 .0 0 5 )。 PCNA标记指数和 Bcl- 2与胸腺瘤肿瘤性质有明显关系 ,Bcl- 2阴性者术后生存率显著高于阳性者 ( P=0 .0 0 2 )。EGFR、PCNA、Bcl- 2和 Bax表达均与胸腺瘤组织学类型、是否合并重症肌无力无明显关系。 结论 EGFR与胸腺瘤的发生、发展有关 ,可作为 Masaoka分期的补充推测预后。Bcl- 2与胸腺癌发生有关 ,可作为胸腺癌的标记物用于鉴别诊断。

氦氖激光穴位照射对兔颞下颌骨关节病软骨细胞Bcl-2与Bax的影响

目的:通过研究氦氖激光对退变颞下颌关节细胞凋亡相关蛋白Bcl-2与Bax表达的影响,明确氦氖激光对颞下颌关节退变的保护作用机制,为临床运用氦氖激光治疗颞下颌关节骨关节病提供依据。方法:将骨骼发育成熟的健康成年雄性新西兰大白兔随机分为正常组、假模型组、模型组和治疗组,每组10只,组内又分为造模成功后第1d、11d两个取材时间点。参照常嘉等的造模方法,建立颞下颌关节骨关节病动物模型并行CT检查证实造模成功后纳入。治疗组采用氦氖激光照射患侧颊车、上关、下关、听宫、翳风穴,5min/穴/天,共10d;假模型组仅作关节囊切开后即缝合组织。运用q PCR检测蛋白多糖4(PRG-4)及骨形态发生蛋白2(BMP-2)m RNA水平,Western Blot方法检测各组织Bcl-2、Bax的蛋白表达水平。结果:正常组及假模型组不同时间点之间软骨基质基因表达无明显差异,建立TMJOA模型后,基因表达降低,基质逐渐降解,氦氖激光治疗10天后,PRG-4及BMP-2表达有所上升;凋亡相关蛋白Bcl-2、Bax的表达在正常组及假模型组之间无显著性差异,造模后抗凋亡蛋白Bcl-2表达减少,而促凋亡蛋白Bax增强;氦氖激光干预10天后Bcl-2的表达较前明显增强,而Bax的表达显著下降。结论:凋亡调节蛋白参与了氦氖激光穴位照射改善颞下颌关节软骨基质的合成与代谢。

The Expression and Significance of CyclinD2,MPGES-1,Bcl2 in Diffuse Large B-cell Lymphoma

Objective:To study the expression and significance of cell cycle proteins CyclinD2,mPGES-1,Bcl2 in diffuse large B-cell lymphoma.Methods:Choose lymphoma and sexually hyper-plastic lymphoid tissues as control.Immunohistoc-hemical methods were used to detect the expression of CyclinD2,mPGES-1,and Bcl2,and to compare the positive expression rates of CyclinD2,MPGES-1 and Bcl2 in diffuse large B-cell lymphoma and reactive proliferative lymphoid tissues to compare their diffusion formation.B-cell lymphoma was analyzed for its clinicopathological features.Results:The positive expression rate of CyclinD2,mPGES-1 and Bcl2 in diffuse large B-cell lymphoma is higher than that in reactive proliferative lymphoid tissue,and the difference between the two is statistically significant.There was no statistical difference in CyclinD2,mPGES-1 and Bcl2 in diffuse large B-cell lymphoma between patients according to the age,sex,location,tissue type and degree of differentiation.Conclusion:CyclinD2,mPGES-1 and Bcl2 are highly expressed in patients with diffuse large B-cell lymphoma,and can be used as reference indicators for evaluating the malignant degree and efficacy of dysplasia.

瑞舒伐他汀对高同型半胱氨酸血症大鼠主动脉Bcl-2与Bax表达的影响

目的:观察瑞舒伐他汀对高同型半胱氨酸血症(hyperhomocysteinemia,Hhcy)Wistar大鼠主动脉组织B细胞淋巴瘤/白血病-2(B cell leukemia/lymphoma-2,Bcl-2)和B细胞淋巴瘤/白血病-2相关蛋白X(Bcl-2-associated X protein,Bax)表达的影响。方法:应用ADVIA2400全自动生化仪检测正常对照组,Hhcy组和瑞舒伐他汀组大鼠的血清甘油三酯、总胆固醇、低密度脂蛋白-胆固醇和血浆同型半胱氨酸(homocysteine,Hcy)浓度;HE染色观察主动脉病理变化;应用免疫组化和实时荧光定量PCR检测主动脉组织Bcl-2、Bax表达。结果:瑞舒伐他汀组大鼠血浆Hcy浓度(10.47±0.07)μmol/L低于Hhcy组(85.38±0.2)μmol/L,差异具有统计学意义(P<0.05);瑞舒伐他汀组大鼠主动脉损伤较Hhcy组减轻;免疫组化显示瑞舒伐他汀组大鼠主动脉Bcl-2蛋白表达比Hhcy组降低,Bax蛋白表达比Hhcy组升高,差异均具有统计学意义(P<0.05);实时荧光定量PCR法显示瑞舒伐他汀组大鼠主动脉Bcl-2 mRNA表达较Hhcy组明显降低,而Bax mRNA表达却升高(P<0.05)。结论:瑞舒伐他汀可能通过降低血浆Hcy浓度及影响主动脉组织Bcl-2、Bax基因表达,从而延缓和改善Hhcy大鼠主动脉粥样硬化的进程及程度。

桂枝芍药知母汤对免疫性关节炎大鼠TNF-α与Bcl-2表达的影响

目的:观察桂枝芍药知母汤对免疫性关节炎大鼠血清中TNF-α与关节滑膜组织Bc l-2表达的影响,并初步探讨其治疗机制。方法:以弗氏完全佐剂诱导产生免疫性关节炎模型,用不同剂量桂枝芍药知母汤(GSZ汤20.6、10.3 g/kg)给模型动物灌胃用药,观察用药后动物血清TNF-α水平与致炎对侧膝关节滑膜组织Bc l-2表达。结果:桂枝芍药知母汤用药4w后,可明显使关节指数减小(P<0.05或P<0.01);使模型大鼠血清TNF-α水平降低(P<0.01);免疫组化染色镜检显示,大鼠膝关节滑膜组织Bc l-2阳性细胞数减少、阳性细胞着色强度减弱(P<0.05或P<0.01),本实验条件下,GSZ汤20.6 g/kg剂量时的疗效与MTX相当。结论:桂枝芍药知母汤对免疫性关节炎大鼠有治疗作用,其机制可能与抑制TNF-α分泌,降低Bc l-2表达有关。

不同剂量活血、破血药对动脉粥样硬化小鼠主动脉Bcl-2及Bax基因表达的影响

目的观察不同剂量活血药(川芎、当归)、破血药(三棱、莪术)对动脉粥样硬化(AS)小鼠主动脉B细胞白血病-淋巴瘤-2(Bcl-2)及B细胞白血病-淋巴瘤-2相关蛋白基因(Bax)表达的影响。方法 64只4周龄Apo E基因敲除小鼠制备AS模型,模型制备成功后随机分为6组:模型对照组(模型组)、阿托伐他汀钙组(他汀组)、低剂量活血药组(低活血组)、低剂量破血药组(低破血组)、高剂量活血药组(高活血组)、高剂量破血药组(高破血组)。连续灌胃给药8周后,处理动物。选用RT-PCR检测主动脉组织Bcl-2及Bax基因m RNA表达并分析比较其结果。结果活血药、破血药均能显著上调Bcl-2、下调Bax基因表达水平(P<0.01)。其中在上调Bcl-2基因表达水平方面,破血药作用优于活血药(P<0.05或P<0.01),且高、低剂量组组间存在显著量效关系(P<0.01);在下调Bax基因表达水平方面,活血药作用显著优于破血药(P<0.01),且高、低剂量组组间存在量效关系(P<0.05或P<0.01)。结论活血药、破血药可通过调节主动脉Bcl-2及Bax基因表达水平,从而起到抗动脉粥样硬化的作用。

Bcl-2蛋白家族在PT孔开放中的作用

PT孔（permeability transition pore，PT孔）是位于线粒体内外膜之间的由多种蛋白组成的复合体。它在线粒体介导的细胞凋亡中起重要作用，开放后会对细胞造成严重后果。PT孔的开放受到多种因素的调节，其中Bcl－2（B－cell lymphoma－2）蛋白家族是重要的调节因子，其可作用于门孔的多个组成蛋白，并均可诱使PT孔开放，从而导致线粒体跨膜电位下降和细胞色素C（CytochromeC，CytC）等物质释放，最终引起细胞凋亡。Bcl-2蛋白家族参与PT孔各组分调控的机制是目前研究的热点，本文就此做一综述。

前列舒通对前列腺增生模型大鼠bcl-2表达的影响

目的:探讨前列舒通对前列腺增生模型大鼠bcl-2表达的影响,观察其对良性前列腺增生的治疗效果。方法:观察前列舒通对由丙酸睾酮诱导的去势大鼠前列腺增生模型后的前列腺指数、bcl-2(抑制细胞凋亡因子)表达以及前列腺组织病理学改变。结果:前列舒通各浓度组前列腺指数、bcl-2表达均明显低于模型组。结论:前列舒通能显著降低良性前列腺增生模型大鼠的bcl-2表达,从而抑制前列腺细胞增殖和促进凋亡而实现抑制良性前列腺增生。

甲钴胺对大鼠坐骨神经损害后背根神经元Bcl-2、Bax表达的影响

目的:探讨甲钴胺对坐骨神经损害后背根神经元保护作用机制。方法:采用SD大鼠,随机分为正常组、模型组和甲钴胺组,预处理14d后制作坐骨神经损害动物模型,分别在模型制备后12h、24h、48h、72h、5d、7d各组提取L1-5背根神经节,免疫组化染色计算Bcl-2、Bax阳性细胞表达数。结果:甲钴胺组于模型制备后12hBcl-2即有明显表达,24～48h达高峰,持续至7d时与模型组比较差异有统计学意义(P<0.05);甲钴胺组Bax表达与同期模型组比较均有不同程度降低,7d时表达水平最低,与模型组比较差异有统计学意义(P<0.05)。结论:甲钴胺的神经元保护作用与其上调Bcl-2蛋白、抑制Bax蛋白的表达有关。